Results for tag: "Ventricular Hypertrophy Drug"

Ventricular Hypertrophy (VH) is a condition in which the walls of the ventricles of the heart become thickened due to an increase in muscle mass. It is a common complication of cardiovascular diseases, such as hypertension, coronary artery disease, and valvular heart disease. Treatment of VH typically involves the use of drugs that reduce the workload of the heart, such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers. These drugs are used to reduce the risk of further complications, such as heart failure and arrhythmias. The Ventricular Hypertrophy Drug market is a subset of the larger Cardiovascular Drugs market. It is composed of drugs that are used to treat VH, as well as other drugs that are used to treat the underlying cardiovascular diseases that can lead to VH. The market is highly competitive, with many large pharmaceutical companies offering a variety of drugs for the treatment of VH. Some of the major companies in the Ventricular Hypertrophy Drug market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. These companies offer a range of drugs for the treatment of VH, including beta-blockers, ACE inhibitors, and calcium channel blockers. Show Less Read more